The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis
Open accessAbstract
Objective: The aim of this review was to synthesize, using random-effects model of meta-analysis, the link between dopaminergic system and Alzheimer’s disease. Methods: A detailed analysis protocol was registered at the PROSPERO database prior to data extraction (CRD42018110798). Electronic databases of PubMed, Embase, Web of Science, and Psyc-ARTICLES were searched up to December 2018 for studies that examined dopamine and dopamine receptors in relation to Alzheimer’s disease. Standardized mean differences (SMD) were calculated to assess group differences in the levels of dopaminergic neurometabolites. Results: Seventeen studies met the eligibility criteria. Collectively, they included 512 patients and 500 healthy controls. There were significantly lower levels of dopamine in patients with Alzheimer’s disease compared with controls (SMD= -1.56, 95% CI: -2.64 to -0.49). In addition, dopamine 1 receptor (SMD=-5.05, 95% CI: -6.14 to -3.97) and dopamine 2 receptor (SMD=-1.13, 95% CI: -1.52 to -0.74) levels were decreased in patients with Alzheimer’s disease compared with controls. The results of network meta-analysis indicated that the rank of correlation with Alzheimer’s disease from highest to lowest was dopamine (0.74), dopamine 2 receptor (0.49), dopamine 3 receptor (0.46), dopamine 4 receptor (0.33), dopamine 5 receptor (0.31), and dopamine 1 receptor (0.64). Conclusions: Overall, decreased levels of dopaminergic neurotransmitters were linked with the pathophysiology of Alzheimer’s disease. Nonetheless, there is a clear need for more prospective studies to validate these hypotheses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125 · cited 1×
“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with complex etiology (Scheltens et al., 2016).”
BackgroundWhite, I. R., Barrett, J. K., Jackson, D., & Higgins, J. P. T. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1045 · Cited by 1,114
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Sex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009
Automating network meta‐analysis
van Valkenhoef, G., Lu, G., de Brock, B., Hillege, H., Ades, A. E., & Welton, N. J. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1054 · Cited by 786
Nobili, A., Latagliata, E. C., Viscomi, M. T., Cavallucci, V., Cutuli, D., Giacovazzo, G., Krashia, P., Rizzo, F. R., Marino, R., Federici, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14727 · Cited by 514 · cited 1×
“For instance, it is widely accepted that dopamine, which derives from the ventral tegmental area (VTA) dopaminergic neurons, modulates and projects mainly cerebral cortex, nucleus accumbens and hippocampal functions, including control of voluntary movement, memory and synaptic plasticity (Nobili et al., 2017).”
BackgroundChanges in the Brain Catecholamines in Patients with Dementia of Alzheimer Type
Adolfsson, R., Gottfries, C. G., Roos, B. E., & Winblad, B. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.135.3.216 · Cited by 449
Cheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.127 · Cited by 409
SEEMAN, P. (1987) · Neuropsychopharmacology · doi:10.1016/0893-133x(87)90004-2 · Cited by 316
Fribourg, M., Moreno, J. L., Holloway, T., Provasi, D., Baki, L., Mahajan, R., Park, G., Adney, S. K., Hatcher, C., Eltit, J. M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.055 · Cited by 311 · cited 1×
“Interestingly, existing research has also decoded the signaling of a GPCR heteromeric complex, which may reveal therapeutic strategies for disorders including Parkinson, schizophrenia and dementia (Fribourg et al., 2011).”
BackgroundKarrer, T. M., Josef, A. K., Mata, R., Morris, E. D., & Samanez-Larkin, G. R. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.006 · Cited by 260
Yates, C. M., Simpson, J., Gordon, A., Maloney, A. F. J., Allison, Y., Ritchie, I. M., & Urquhart, A. (1983) · Brain Research · doi:10.1016/0006-8993(83)91179-4 · Cited by 251
Salivary cortisol in post-traumatic stress disorder: a systematic review and meta-analysis
Pan, X., Wang, Z., Wu, X., Wen, S. W., & Liu, A. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1910-9 · Cited by 193
Self-citationHerrmann, N., Rothenburg, L. S., Black, S. E., Ryan, M., Liu, B. A., Busto, U. E., & Lanctôt, K. L. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b479 · Cited by 169
Gray matter atrophy pattern in elderly with subjective memory impairment
Peter, J., Scheef, L., Abdulkadir, A., Boecker, H., Heneka, M., Wagner, M., Koppara, A., Klöppel, S., Jessen, F., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1764 · Cited by 165
Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease
Kemppainen, N., Laine, M., Laakso, M. P., Kaasinen, V., Någren, K., Vahlberg, T., Kurki, T., & Rinne, J. O. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02716.x · Cited by 165
Dopaminergic Modulation of Cortical Plasticity in Alzheimer’s Disease Patients
Koch, G., Lorenzo, F. D., Bonnì, S., Giacobbe, V., Bozzali, M., Caltagirone, C., & Martorana, A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.119 · Cited by 162
The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease
Mitchell, R. A., Herrmann, N., & Lanctôt, K. L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00161.x · Cited by 153
Dopamine Modulates Cholinergic Cortical Excitability in Alzheimer's Disease Patients
Martorana, A., Mori, F., Esposito, Z., Kusayanagi, H., Monteleone, F., Codecà, C., Sancesario, G., Bernardi, G., & Koch, G. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.60 · Cited by 150
Ehrin, E., Farde, L., de Paulis, T., Eriksson, L., Greitz, T. V. B., Johnström, P., Litton, J., Nilsson, J., Sedvall, G., Stone‐Elander, S., et al. (1985) · The International Journal of Applied Radiation and Isotopes · doi:10.1016/0020-708x(85)90083-3 · Cited by 140
Kumar, U., & Patel, S. C. (2006) · Brain Research · doi:10.1016/j.brainres.2006.10.049 · Cited by 125
Catecholamines in Post-traumatic Stress Disorder: A Systematic Review and Meta-Analysis
Pan, X., Kaminga, A. C., Wen, S. W., & Liu, A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00450 · Cited by 117
Self-citationDopaminergic modulation of cognition across the life span
Li, S., Lindenberger, U., & Bäckman, L. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.02.003 · Cited by 113
Umegaki, H., Ikari, H., Nakahata, H., Endo, H., Suzuki, Y., Ogawa, O., Nakamura, A., Yamamoto, T., & Iguchi, A. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02847-x · Cited by 110
Basic Concepts in G-Protein-Coupled Receptor Homo- and Heterodimerization
Franco, R., Casadó, V., Cortés, A., Ferrada, C., Mallol, J., Woods, A. S., Lluís, C., Canela, E. I., & Ferré, S. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.197 · Cited by 107
Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain
López‐Bastida, J., Serrano‐Aguilar, P., Perestelo‐Pérez, L., & Oliva, J. (2006) · Neurology · doi:10.1212/01.wnl.0000249311.80411.93 · Cited by 99
Martorana, A., Lorenzo, F. D., Esposito, Z., Giudice, T. L., Bernardi, G., Caltagirone, C., & Koch, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.015 · Cited by 96
Mintzer, J., Greenspan, A., Caers, I., Van Hove, I., Kushner, S., Weiner, M., Gharabawi, G., & Schneider, L. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000194643.63245.8c · Cited by 94 · cited 1×
“Another prospective clinical trial showed that treatment of a dopamine receptor antagonist, risperidone, in more severe dementia was showing significant therapeutic effect, but not significant in other subgroups (Mintzer et al., 2006).”
BackgroundDetection of dopamine receptors in the area postrema
Stefanini, E., & Clement‐Cormier, Y. C. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90540-9 · Cited by 92
Dopamine and cognitive functioning: Brain imaging findings in Huntington’s disease and normal aging
Bäckman, L., & Farde, L. (2001) · Scandinavian Journal of Psychology · doi:10.1111/1467-9450.00238 · Cited by 92
Barnum, D. W. (1977) · Analytica Chimica Acta · doi:10.1016/s0003-2670(01)83081-6 · Cited by 89
Nam, E., Derrick, J. S., Lee, S., Kang, J., Han, J., Lee, S. J. C., Chung, S. W., & Lim, M. H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00122 · Cited by 89
Sweet, R. A., Hamilton, R. L., Healy, M. T., Wisniewski, S. R., Henteleff, R. A., Pollock, B. G., Lewis, D. A., & DeKosky, S. T. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.466 · Cited by 87
The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1
Booth, T. C., Nathan, M., Waldman, A. D., Quigley, A., Schapira, A. H. V., & Buscombe, J. R. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3970 · Cited by 85
Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation
Donthamsetti, P., Gallo, E. F., Buck, D. C., Stahl, E. L., Zhu, Y., Lane, J. R., Bohn, L., Neve, K. A., Kellendonk, C., & Javitch, J. A. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0212-4 · Cited by 82
Giacobini, E., & Pepeu, G. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180613111504 · Cited by 79
Striatal dopamine receptors in Alzheimer-type dementia
Cross, A. J., Crow, T. J., Ferrier, I. N., Johnson, J. A., & Markakis, D. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90341-0 · Cited by 78
Initiative, A. D. N., Roostaei, T., Nazeri, A., Felsky, D., Jager, P. L. D., Schneider, J. A., Pollock, B. G., Bennett, D. A., & Voineskos, A. N. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.35 · Cited by 74
Oxidative stress in Alzheimer disease as a target for therapy
Pohanka, M. (2018) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2018_097 · Cited by 74
Devanand, D. P., Pelton, G. H., Cunqueiro, K., Sackeïm, H. A., & Marder, K. S. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2630 · Cited by 70
Borba, E. M., Duarte, J. A., Bristot, G., Scotton, E., Camozzato, A. L., & Chaves, M. L. F. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000450601 · Cited by 67
Loss of Dopamine Uptake Sites Labeled with [ 3 H]GBR-12935 in Alzheimer’s Disease
Allard, P., Alafuzoff, I., Carlsson, A., Eriksson, K., Ericson, E., Gottfries, C.-G., & Marcusson, J. O. (2008) · European Neurology · doi:10.1159/000117341 · Cited by 64
Targeting the dopamine D3 receptor: an overview of drug design strategies
Cortés, A., Moreno, E., Rodríguez-Ruiz, M., Canela, E. I., & Casadó, V. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1185413 · Cited by 62
Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer's disease
Joyce, J. N., Kaeger, C., Ryoo, H., & Goldsmith, S. K. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90199-u · Cited by 55
Tiernan, C. T., Ginsberg, S. D., He, B., Ward, S., Guillozet-Bongaarts, A. L., Kanaan, N. M., Mufson, E. J., & Counts, S. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.021 · Cited by 51
De Keyser, J., Ebinger, G., & Vauquelin, G. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530070055011 · Cited by 49
Apathy Associated with Alzheimer Disease: Use of Dextroamphetamine Challenge
Lanctôt, K. L., Herrmann, N., Black, S. E., Ryan, M., Rothenburg, L. S., Liu, B. A., & Busto, U. E. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318170a6d1 · Cited by 48
Nardone, R., Höller, Y., Thomschewski, A. C., Kunz, A. B., Lochner, P., Golaszewski, S. M., Trinka, E., & Brigo, F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1195-1 · Cited by 46
Joyce, J., Murray, A., Hurtig, H., Gottlieb, G., & Trojanowski, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00044-x · Cited by 43
Cortés, R., Probst, A., & Palacios, J. M. (1988) · Brain Research · doi:10.1016/0006-8993(88)90212-0 · Cited by 41
Saqib, M., Bashir, S., Li, H., Wang, S., & Jin, Y. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05486 · Cited by 38
Shinohara, H., & Wang, F. (2007) · Analytical Sciences · doi:10.2116/analsci.23.81 · Cited by 35
Hagena, H., & Manahan‐Vaughan, D. (2016) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2016.00031 · Cited by 34
Evidence for the heterotetrameric structure of the adenosine A2A–dopamine D2 receptor complex
Casadó-Anguera, V., Bonaventura, J., Moreno, E., Navarro, G., Cortés, A., Ferré, S., & Casadó, V. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150276 · Cited by 32
Amantadine for Executive Dysfunction Syndrome in Patients With Dementia
Drayton, S. J., Davies, K., Steinberg, M., Leroi, I., Rosenblatt, A., & Lyketsos, C. G. (2004) · Psychosomatics · doi:10.1176/appi.psy.45.3.205 · Cited by 25
Belbin, O., Morgan, K., Medway, C., Warden, D. R., Cortina‐Borja, M., van Duijn, C. M., Adams, H. H. H., Frank, A., Brookes, K. J., Sánchez‐Juan, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181116 · Cited by 21
Dekker, A. D., Vermeiren, Y., Carmona‐Iragui, M., Benejam, B., Videla, L., Gelpí, E., Aerts, T., Dam, D. V., Fernández, S., Lleó, A., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.11.001 · Cited by 17
Westerink, B. H. C., & van Oene, J. C. (1980) · European Journal of Pharmacology · doi:10.1016/0014-2999(80)90210-1 · Cited by 16
Detection of Cell Surface Dopamine Receptors
Xiao, J., & Bergson, C. M. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-251-3_1 · Cited by 7
Cited by
Chen, C., Liao, J., Xia, Y., Liu, X., Jones, R., Haran, J., McCormick, B., Sampson, T. R., Alam, A., & Ye, K. (2022) · Gut · doi:10.1136/gutjnl-2021-326269 · Cited by 491
Biosensors and sensors for dopamine detection
Liu, X., & Liu, J. (2021) · VIEW · doi:10.1002/viw.20200102 · Cited by 329
Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
Wu, Y., Liu, Q., Qiu, Y., & Xie, L. (2022) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010367 · Cited by 34
Preserved autophagy in cognitively intact non‐demented individuals with Alzheimer's neuropathology
Tumurbaatar, B., Fracassi, A., Scaduto, P., Guptarak, J., Woltjer, R., Jupiter, D., & Taglialatela, G. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13074 · Cited by 32
Metadata
- Authors
- Pan, X., Kaminga, A. C., Wen, S. W., Wu, X., Acheampong, K., & Liu, A.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-07-11
- Volume
- 11
- Pages
- 175-175
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2956927868
- Cited by
- 268
- References
- 63
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.